Breaking News Instant updates and real-time market news.

ORLY

O'Reilly Automotive

$376.04

-8.62 (-2.24%)

, AAP

Advance Auto Parts

$164.90

-4.11 (-2.43%)

06:48
03/25/19
03/25
06:48
03/25/19
06:48

O'Reilly Automotive added to Analyst Focus List at JPMorgan

JPMorgan analyst Christopher Horvers added O'Reilly Automotive (ORLY) to his firm's Analyst Focus List following his "weather deep dive." 2019's winter has been "solid" but not as good as 2018 due to snowfall levels, Horvers tells investors in a research note. He points out that autoparts demand is "quite sensitive" to extreme weather trends. The analyst believes the 2019 winter benefits O'Reilly the most among the "big 4," which also includes Advance Auto Parts (AAP), AutoZone (AZO) and Genuine Parts (GPC). Horvers keeps an Overweight rating on O'Reilly Automotive with a $398 price target.

ORLY

O'Reilly Automotive

$376.04

-8.62 (-2.24%)

AAP

Advance Auto Parts

$164.90

-4.11 (-2.43%)

AZO

AutoZone

$981.27

-20.44 (-2.04%)

GPC

Genuine Parts

$107.51

-1.59 (-1.46%)

  • 25

    Mar

  • 26

    Mar

  • 04

    Apr

  • 22

    Apr

ORLY O'Reilly Automotive
$376.04

-8.62 (-2.24%)

03/20/19
EVER
03/20/19
INITIATION
Target $375
EVER
In Line
O'Reilly Automotive initiated with an In Line at Evercore ISI
Evercore ISI analyst Greg Melich initiated O'Reilly Automotive with an In Line rating and $375 base case price target, citing his view that a comp acceleration to over 7% is needed to sustain a P/E re-rating.
03/11/19
BOFA
03/11/19
UPGRADE
Target $1080
BOFA
Buy
BofA/Merrill upgrades AutoZone to Buy on strong fundamentals
As previously reported, BofA analyst Elizabeth Suzuki upgraded AutoZone (AZO) to Buy from Neutral and raised her price target on the stock to $1,080 from $987 as she does not think that the rally for auto parts stocks is over and she believes that AutoZone's valuation discount to the group should narrow as it grows its commercial business. Suzuki also raised her price target on O'Reilly Automotive (ORLY) shares to $415 from $390.
03/01/19
03/01/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. L Brands (LB) downgraded to Market Perform from Outperform at Bernstein with analyst Jamie Merriman saying her Outperform rating was based on a view that investors were paying for Bath & Body Works with a free option on Victoria's Secret. 2. American Airlines (AAL) and Delta Air Lines (DAL) downgraded to Hold from Buy at Deutsche Bank. 3. Devon Energy (DVN) downgraded to Sector Perform from Outperform at RBC Capital. 4. O'Reilly Automotive (ORLY) downgraded to Neutral from Overweight at Atlantic Equities with analyst Sam Hudson citing valuation and raised his price target to $400 from $370. 5. Maxar Technologies (MAXR) downgraded to Hold from Speculative Buy at TD Securities and to Underperformer from Neutral at CIBC. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/01/19
ATLE
03/01/19
DOWNGRADE
Target $400
ATLE
Neutral
O'Reilly Automotive downgraded to Neutral from Overweight at Atlantic Equities
Atlantic Equities analyst Sam Hudson downgraded O'Reilly Automotive to Neutral from Overweight citing valuation and raised his price target to $400 from $370.
AAP Advance Auto Parts
$164.90

-4.11 (-2.43%)

01/09/19
BOFA
01/09/19
UPGRADE
BOFA
Buy
Advance Auto Parts upgraded to Buy on valuation at BofA/Merrill
As previously reported, BofA/Merrill upgraded Advance Auto Parts to Buy from Neutral and maintained a $200 price target. Analyst Elizabeth Suzuki said the recent pullback provides a buying opportunity combined with a strengthening macro backdrop for Advance Auto's addressable market. The analyst is forecasting above-average growth due to its high exposure to the accelerating DIFM market, which will drive comp and margin improvement.
03/20/19
EVER
03/20/19
INITIATION
Target $185
EVER
Outperform
Advance Auto Parts initiated with an Outperform at Evercore ISI
Evercore ISI analyst Greg Melich initiated Advance Auto Parts with an Outperform rating and $185 base case price target, given his view that its retail turnaround is gaining momentum against a solid industry backdrop.
02/20/19
JEFF
02/20/19
NO CHANGE
Target $195
JEFF
Buy
Advance Auto Parts price target lowered to $195 from $215 at Jefferies
Jefferies analyst Bret Jordan lowered his price target for Advance Auto Parts to $195 following the company's Q4 results and keeps a Buy rating on the shares. The fiscal 2019 comp guidance of up 1.0% to 2.5% appears conservative, as inflation alone should generate greater than 1% sales growth while Advance Auto also expects to gain share, Jordan tells investors in a post-earnings research note. While fiscal 2019 will see "significant" technology investment, the analyst expects accelerating margin gains in fiscal 2020. Jordan keeps a Buy rating on the shares.
02/20/19
MSCO
02/20/19
NO CHANGE
Target $205
MSCO
Overweight
Advance Auto Parts' 'decent' guidance may disappoint bulls, says Morgan Stanley
Morgan Stanley analyst Simeon Gutman called Advance Auto Parts' 2019 guidance for 1%-2.5% comp growth and 20-60 bps of EBIT margin expansion "decent," but believes it will be disappointing for bulls. However, he thinks there could be margin upside in 2019 given that he believes comp guidance is likely conservative, top-line initiatives should result in market share gains and he sees sales upside flowing through to the bottom line. Gutman, who thinks the stock is pricing in 2.5% comps and 50 bps of annual EBIT margin expansion over the next three years, keeps an Overweight rating and $205 price target on Advance Auto Parts shares.
AZO AutoZone
$981.27

-20.44 (-2.04%)

03/11/19
BOFA
03/11/19
UPGRADE
BOFA
Buy
AutoZone upgraded to Buy from Neutral at BofA/Merrill
03/11/19
03/11/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Apple (AAPL) upgraded to Buy from Neutral at BofA/Merrill with analyst Wamsi Mohan saying he now sees "stability" of supply chain order cuts and a "large reversal of inventory overhang" in iPhones. He believes negative consensus estimates revisions for fiscal 2020 and 2021 have overshot to the downside and that the valuation, excluding Apple's cash position, is attractive. The analyst also raised his price target for the shares to $210 from $180. 2. Facebook (FB) upgraded to Buy from Neutral at Nomura Instinet with analyst Mark Kelley saying Facebook's transition to Stories appears to be occurring more quickly than we expected. 3. FireEye (FEYE) upgraded to Overweight from Neutral at JPMorgan with analyst Sterling Auty saying the stock's year-to-date performance has been 23% below the group's coverage, and the stock is now trading at 3.7 times estimated fiscal 2019 revenue estimates. 4. Spirit Airlines (SAVE) upgraded to Overweight from Equal Weight at Barclays with analyst Brandon Oglenski raising his price target for the shares to $70 from $65. 5. AutoZone (AZO) upgraded to Buy from Neutral at BofA/Merrill with analyst Elizabeth Suzuki saying she does not think that the rally for auto parts stocks is over and she believes that AutoZone's valuation discount to the group should narrow as it grows its commercial business. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/20/19
EVER
03/20/19
INITIATION
Target $1030
EVER
In Line
AutoZone initiated with an In Line at Evercore ISI
Evercore ISI analyst Greg Melich initiated AutoZone (AZO) with an In Line rating and $1,030 base case price target, stating that he favors the risk-reward at Advance Auto (AAP) with AutoZone shares trading at all-time highs.
GPC Genuine Parts
$107.51

-1.59 (-1.46%)

10/30/18
10/30/18
DOWNGRADE
Target $105

Underperform
Genuine Parts downgraded to Underperform at BofA/Merrill
As previously reported, BofA/Merrill downgraded Genuine Parts to Underperform from Neutral and maintained a $105 price target. Analyst Elizabeth Suzuki said the termination of the office products division S.P. Richards, to Essendant leaves the company with an asset that lowers Genuine Parts' margins and growth profile. The analyst expects the unit to to post negative comps for the foreseeable future, with operating margins below the company average.
03/20/19
EVER
03/20/19
INITIATION
Target $110
EVER
In Line
Genuine Parts initiated with an In Line at Evercore ISI
Evercore ISI analyst Greg Melich initiated Genuine Parts with an In Line rating and $110 base case price target, citing his questions about the sustainability of its recent strength given that he believes both Industrial and the European portion of its auto parts businesses may soften this year.
01/09/19
BOFA
01/09/19
UPGRADE
BOFA
Neutral
Genuine Parts upgraded to Neutral from Underperform at BofA/Merrill
01/09/19
01/09/19
UPGRADE

Neutral
Genuine Parts upgraded to Neutral at BofA/Merrill
As previously reported, BofA/Merrill upgraded Genuine Parts to Neutral from Underperform and maintained a $105 price target. Analyst Elizabeth Suzuki expects the auto segment to see accelerating growth trends, but expects other segments to decelerate, offsetting the auto cycle benefit.

TODAY'S FREE FLY STORIES

EPZM

Epizyme

$18.22

2.9 (18.93%)

10:09
12/07/19
12/07
10:09
12/07/19
10:09
Hot Stocks
Epizyme announces 'positive, mature data' for Phase 2 trial of tazemetostat »

Epizyme reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 18

    Dec

  • 23

    Jan

PRNB

Principia Biopharma

$37.30

0.86 (2.36%)

10:07
12/07/19
12/07
10:07
12/07/19
10:07
Hot Stocks
Principia Biopharma announces 'consistent positive data' for PRN1008 »

Principia Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$200.99

1.64 (0.82%)

, GOOGL

Alphabet Class A

$1,339.41

11.6 (0.87%)

09:31
12/07/19
12/07
09:31
12/07/19
09:31
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

FB

Facebook

$200.99

1.64 (0.82%)

GOOGL

Alphabet Class A

$1,339.41

11.6 (0.87%)

GOOG

Alphabet

$1,341.23

12.23 (0.92%)

AAPL

Apple

$270.71

5.15 (1.94%)

AMZN

Amazon.com

$1,750.79

10.2 (0.59%)

SQ

Square

$68.00

0.85 (1.27%)

TWTR

Twitter

$30.19

0.16 (0.53%)

CSIQ

Canadian Solar

$18.35

0.39 (2.17%)

FSLR

First Solar

$53.36

1.06 (2.03%)

JASO

JA Solar

$0.00

(0.00%)

SPWR

SunPower

$7.23

0.15 (2.12%)

TSL

Trina Solar

$0.00

(0.00%)

YGE

Yingli Green Energy

$0.00

(0.00%)

AKS

AK Steel

$3.24

0.065 (2.05%)

MT

ArcelorMittal

$17.88

0.43 (2.46%)

NUE

Nucor

$57.60

1.13 (2.00%)

STLD

Steel Dynamics

$35.10

0.67 (1.95%)

TMST

TimkenSteel

$6.90

0.41 (6.32%)

X

U.S. Steel

$13.95

0.615 (4.61%)

AA

Alcoa

$20.60

0.68 (3.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 06

    Feb

  • 26

    Feb

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

09:27
12/07/19
12/07
09:27
12/07/19
09:27
Hot Stocks
Fate Therapeutics reports initial clinical data for FT516 and FT50 »

Fate Therapeutics …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

09:25
12/07/19
12/07
09:25
12/07/19
09:25
Conference/Events
JPMorgan enterprise software analyst to hold an analyst/industry conference call »

Software Analyst Murphy,…

CRVS

Corvus Pharmaceuticals

$4.26

-0.36 (-7.79%)

09:23
12/07/19
12/07
09:23
12/07/19
09:23
Hot Stocks
Corvus reports initial results from Phase 1/1b trial of CPI-818 »

Corvus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KPTI

Karyopharm

$16.30

-1.15 (-6.59%)

09:21
12/07/19
12/07
09:21
12/07/19
09:21
Hot Stocks
Karyopharm announces updated Xpovio data in multiple myeloma »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

09:18
12/07/19
12/07
09:18
12/07/19
09:18
Hot Stocks
AbbVie reports results of 7.5-year pooled analysis of Imbruvica »

AbbVie announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

09:16
12/07/19
12/07
09:16
12/07/19
09:16
Hot Stocks
Sierra Oncology reports new analyses of momelotinib compared to ruxolitinib »

Sierra Oncology reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

SGMO

Sangamo

$11.65

0.05 (0.43%)

, PFE

Pfizer

$38.29

0.26 (0.68%)

09:14
12/07/19
12/07
09:14
12/07/19
09:14
Hot Stocks
Sangamo, Pfizer announce follow-up results from Phase 1/2 hemophilia A.study »

Sangamo Therapeutics…

SGMO

Sangamo

$11.65

0.05 (0.43%)

PFE

Pfizer

$38.29

0.26 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 11

    Dec

VSTM

Verastem

$1.31

0.055 (4.38%)

09:12
12/07/19
12/07
09:12
12/07/19
09:12
Hot Stocks
Verastem announces 62% response rate for duvelisib in T-cell lymphoma »

Verastem announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

RHHBY

Roche

$0.00

(0.00%)

09:09
12/07/19
12/07
09:09
12/07/19
09:09
Hot Stocks
Genentech announces new data on CD20-CD3 T-cell in Hodgkin's lymphoma »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 16

    Dec

XENE

Xenon Pharmaceuticals

$13.92

0.03 (0.22%)

, BMRN

BioMarin

$79.90

-0.18 (-0.22%)

08:59
12/07/19
12/07
08:59
12/07/19
08:59
Hot Stocks
Xenon to provide updates on partnered epilepsy programs »

Xenon Pharmaceuticals…

XENE

Xenon Pharmaceuticals

$13.92

0.03 (0.22%)

BMRN

BioMarin

$79.90

-0.18 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

CLF

Cleveland-Cliffs

$8.14

0.2 (2.52%)

, AKS

AK Steel

$3.24

0.065 (2.05%)

08:56
12/07/19
12/07
08:56
12/07/19
08:56
Recommendations
Cleveland-Cliffs, AK Steel analyst commentary  »

Cleveland-Cliffs shares…

CLF

Cleveland-Cliffs

$8.14

0.2 (2.52%)

AKS

AK Steel

$3.24

0.065 (2.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

M

Macy's

$15.15

0.04 (0.26%)

08:53
12/07/19
12/07
08:53
12/07/19
08:53
Periodicals
Barron's skeptical on Macy's shares into the holiday season »

The turnaround at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COF

Capital One

$101.39

1.8 (1.81%)

08:43
12/07/19
12/07
08:43
12/07/19
08:43
Periodicals
Capital One shares could have more upside ahead, Barron's says »

Shares of Capital One…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

EXPE

Expedia

$107.58

1.9 (1.80%)

08:26
12/07/19
12/07
08:26
12/07/19
08:26
Periodicals
Expedia shares still a buy despite management changes, Barron's says »

Shares of Expedia remain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

DAR

Darling Ingredients

$24.05

0.39 (1.65%)

, CODI

Compass Diversified

$23.88

0.45 (1.92%)

08:21
12/07/19
12/07
08:21
12/07/19
08:21
Periodicals
Darling, Qualys among small-caps to own for 2020 breakout, Barron's says »

In its weekend cover…

DAR

Darling Ingredients

$24.05

0.39 (1.65%)

CODI

Compass Diversified

$23.88

0.45 (1.92%)

QLYS

Qualys

$85.37

-0.37 (-0.43%)

LECO

Lincoln Electric

$92.52

0.69 (0.75%)

HASI

Hannon Armstrong

$29.50

0.24 (0.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 12

    Dec

CBMG

Cellular Biomedicine

$17.56

0.18 (1.04%)

08:11
12/07/19
12/07
08:11
12/07/19
08:11
Hot Stocks
Cellular Biomedicine presents first clinical data of C-CAR088 in myeloma »

Cellular Biomedicine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

AXLA

Axcella

$3.63

-0.83 (-18.61%)

08:07
12/07/19
12/07
08:07
12/07/19
08:07
Hot Stocks
Axcella says preclinical of AXA4010 data show multifactorial potential »

Axcella Health announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$47.68

0.06 (0.13%)

08:04
12/07/19
12/07
08:04
12/07/19
08:04
Hot Stocks
AstraZeneca says Calquence combination improved survival in leukemia patients »

AstraZeneca presented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

08:01
12/07/19
12/07
08:01
12/07/19
08:01
Hot Stocks
AbbVie announces follow-up data from chronic lymphocytic leukemia study »

AbbVie announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

07:56
12/07/19
12/07
07:56
12/07/19
07:56
Hot Stocks
AbbVie announces data from Phase 2 lymphocytic leukemia study »

AbbVie announced new data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

07:51
12/07/19
12/07
07:51
12/07/19
07:51
Hot Stocks
Janssen announces initial results from Phase 1b/2 multiple myeloma study »

Janssen Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 21

    Jan

XBIT

XBiotech

$11.11

0.1 (0.91%)

, JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

07:46
12/07/19
12/07
07:46
12/07/19
07:46
Hot Stocks
XBiotech sells bermekimab to Janssen for $750M plus potential milestones »

XBiotech (XBIT) announced…

XBIT

XBiotech

$11.11

0.1 (0.91%)

JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 21

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.